Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States

International Journal of Cardiology

Volumn 212, Issue , 2016, Pages 171-173

  Coleman, Craig I ^a   Tangirala, Muralikrishna ^b   Evers, Thomas ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

Dabigatran; Medication adherence; Non valvular atrial fibrillation; Proportion of days covered; Rivaroxaban

Indexed keywords

DABIGATRAN; RIVAROXABAN;

AGED; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; COMPARATIVE STUDY; MIDDLE AGED; PROPENSITY SCORE; STATISTICS AND NUMERICAL DATA; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; TREATMENT OUTCOME; UNITED STATES;

EID: 84961943279     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.051     Document Type: Article

References (10)

1. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, and et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
2. S. Shore, E.P. Carey, M.P. Turakhia, C.A. Jackevicius, F. Cunningham, L. Pilote, and et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the veterans health administration Am Heart J 167 2014 810 817
3. E. Danielson Health research data for the real world: The MarketScan database 2014 Available at: Http://truvenhealth.com/Portals/0/Users/031/31/31/PH-13434%200314-MarketScan-WP-web.pdf
4. D.A. Lane, and G.Y. Lip Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation Circulation 126 2012 860 865
5. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
6. P.C. Austin Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research Commun Stat Simul Comput 38 2009 1228 1234
7. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 40 1987 373 383
8. M.C. Fang, A.S. Go, Y. Chang, and et al. A new risk scheme to predict warfarin associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study J Am Coll Cardiol 58 2011 395 401
9. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
10. C.I. Coleman, M.S. Roberts, D.M. Sobieraj, S. Lee, T. Alam, and R. Kaur Effect of dosing frequency on chronic cardiovascular disease medication adherence Curr Med Res Opin 28 2012 669 680